Bifidobacterium breve BBG-001,
does it really help with Prevention of NEC, sepsis, or death in very preterm infants?
research showsGrade D. In 1,315 infants, sepsis was 11.2% with BBG-001 vs 11.7% with placebo (adjusted RR 0.97, 95% CI 0.73-1.29; absolute difference -0.5 points), NEC 9.4% vs 10.0% (0.93, 0.68-1.27; -0.6), and death 8.3% vs 8.5% (0.93, 0.67-1.30; -0.2).
ads claimBenefits from another strain or combination cannot be transferred to BBG-001.
Useful facts when choosing a product
- BBG-001 or placebo was given daily.
- NIHR HTA funded the research; Yakult Honsha manufactured and transported probiotic and placebo free of charge but did not participate in design, conduct, or analysis.
- Cross-colonization occurred in placebo infants.
What the research actually shows
Verdict 2927 adds IVIG after neonatal sepsis is suspected or proven; this trial tested prevention in very preterm infants. Funding and COI disclosures state that NIHR funded the research and Yakult Honsha Co. Ltd manufactured and transported the probiotic and placebo to the UK free of charge, without involvement in design, conduct, or analysis. Placebo-arm cross-colonization occurred, but planned analyses did not suggest it explained the null result. It is not a listed Axis 6 defect and was retained only as context. Verdict 1503 found benefit for a combination probiotic in the same indication: outcomes differ by strain even within the same indication.
Why this is classified as D (34)
One 1,315-infant null hard-outcome trial, with company trial-product provision scored I1, gives D with 34 points.
Counterpoint. Combination probiotics are a separate strain-specific question.
Rejudgment record. Cross-check applied — A 1,315-infant publicly funded prevention RCT was null for all three hard outcomes
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of NEC, sepsis, or death | D | All were null. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| PiPS 2015 | Multicenter double-blind placebo-controlled RCT | 1,315 | National Institute for Health Research Health Technology Assessment programme funding; Yakult Honsha Co. Ltd manufactured and transported the probiotic and placebo to the UK free of charge and had no involvement in design, conduct, or analysis | Sepsis, Bell stage 2 or greater NEC, and death before discharge | Sepsis 11.2% with BBG-001 vs 11.7% with placebo, absolute difference -0.5 points, adjusted RR 0.97 (95% CI 0.73-1.29); NEC 9.4% vs 10.0%; death 8.3% vs 8.5% | Large NIHR-funded hard-outcome prevention trial with free company provision of trial products |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] No Benefit of Bifidobacterium breve BBG-001 for Necrotizing Enterocolitis, Sepsis, or Death in Very Preterm Infants — Evidence Grade D·34. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/bifidobacterium-breve-bbg-001-very-preterm-nec-sepsis-death/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.